65 related articles for article (PubMed ID: 16033849)
1. Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy.
Friess T; Scheuer W; Hasmann M
Clin Cancer Res; 2005 Jul; 11(14):5300-9. PubMed ID: 16033849
[TBL] [Abstract][Full Text] [Related]
2. Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model.
Bozec A; Sudaka A; Fischel JL; Brunstein MC; Etienne-Grimaldi MC; Milano G
Br J Cancer; 2008 Jul; 99(1):93-9. PubMed ID: 18577994
[TBL] [Abstract][Full Text] [Related]
3. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab.
Adams CW; Allison DE; Flagella K; Presta L; Clarke J; Dybdal N; McKeever K; Sliwkowski MX
Cancer Immunol Immunother; 2006 Jun; 55(6):717-27. PubMed ID: 16151804
[TBL] [Abstract][Full Text] [Related]
4. Erratum to Discovery of a Novel Potent Antitumor Molecule, P19G1, by Erlotinib Derivative.
Technol Cancer Res Treat; 2023; 22():15330338221149552. PubMed ID: 36632663
[No Abstract] [Full Text] [Related]
5. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models.
Yamashita-Kashima Y; Iijima S; Yorozu K; Furugaki K; Kurasawa M; Ohta M; Fujimoto-Ouchi K
Clin Cancer Res; 2011 Aug; 17(15):5060-70. PubMed ID: 21700765
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Potential of Fingolimod and Dimethyl Fumarate in Non-Small Cell Lung Cancer Preclinical Models.
Rupp T; Debasly S; Genest L; Froget G; Castagné V
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897763
[TBL] [Abstract][Full Text] [Related]
7. Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy.
MacNeil IA; Khan SA; Sen A; Soltani SM; Burns DJ; Sullivan BF; Laing LG
Cell Commun Signal; 2022 Jan; 20(1):4. PubMed ID: 34998412
[TBL] [Abstract][Full Text] [Related]
8. Histological validation of in vivo assessment of cancer tissue inhomogeneity and automated morphological segmentation enabled by Optical Coherence Elastography.
Plekhanov AA; Sirotkina MA; Sovetsky AA; Gubarkova EV; Kuznetsov SS; Matveyev AL; Matveev LA; Zagaynova EV; Gladkova ND; Zaitsev VY
Sci Rep; 2020 Jul; 10(1):11781. PubMed ID: 32678175
[TBL] [Abstract][Full Text] [Related]
9.
Sirotkina MA; Gubarkova EV; Plekhanov AA; Sovetsky AA; Elagin VV; Matveyev AL; Matveev LA; Kuznetsov SS; Zagaynova EV; Gladkova ND; Zaitsev VY
Biomed Opt Express; 2020 Mar; 11(3):1365-1382. PubMed ID: 32206416
[TBL] [Abstract][Full Text] [Related]
10. Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes.
Yang Z; Tam KY
Int J Biol Sci; 2018; 14(2):204-216. PubMed ID: 29483838
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines.
La Monica S; Cretella D; Bonelli M; Fumarola C; Cavazzoni A; Digiacomo G; Flammini L; Barocelli E; Minari R; Naldi N; Petronini PG; Tiseo M; Alfieri R
J Exp Clin Cancer Res; 2017 Dec; 36(1):174. PubMed ID: 29202823
[TBL] [Abstract][Full Text] [Related]
12. siRNA-mediated inactivation of HER3 improves the antitumour activity and sensitivity of gefitinib in gastric cancer cells.
Yuan HH; Yang YN; Zhou JH; Li YJ; Wang LY; Qin JW; Liu T; Li ZZ; Zhou QX; Wei XL; Zhang TT; Huang P; Zhang WJ; Liu L; Du XX; Han Y
Oncotarget; 2017 Aug; 8(32):52584-52593. PubMed ID: 28881753
[TBL] [Abstract][Full Text] [Related]
13. Photodynamic therapy monitoring with optical coherence angiography.
Sirotkina MA; Matveev LA; Shirmanova MV; Zaitsev VY; Buyanova NL; Elagin VV; Gelikonov GV; Kuznetsov SS; Kiseleva EB; Moiseev AA; Gamayunov SV; Zagaynova EV; Feldchtein FI; Vitkin A; Gladkova ND
Sci Rep; 2017 Feb; 7():41506. PubMed ID: 28148963
[TBL] [Abstract][Full Text] [Related]
14. HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone.
Day KC; Lorenzatti Hiles G; Kozminsky M; Dawsey SJ; Paul A; Broses LJ; Shah R; Kunja LP; Hall C; Palanisamy N; Daignault-Newton S; El-Sawy L; Wilson SJ; Chou A; Ignatoski KW; Keller E; Thomas D; Nagrath S; Morgan T; Day ML
Cancer Res; 2017 Jan; 77(1):74-85. PubMed ID: 27793843
[TBL] [Abstract][Full Text] [Related]
15. Improved decision making for prioritizing tumor targeting antibodies in human xenografts: Utility of fluorescence imaging to verify tumor target expression, antibody binding and optimization of dosage and application schedule.
Dobosz M; Haupt U; Scheuer W
MAbs; 2017 Jan; 9(1):140-153. PubMed ID: 27661454
[TBL] [Abstract][Full Text] [Related]
16. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
[TBL] [Abstract][Full Text] [Related]
17. A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer.
Kaur S; Elkahloun AG; Singh SP; Chen QR; Meerzaman DM; Song T; Manu N; Wu W; Mannan P; Garfield SH; Roberts DD
Oncotarget; 2016 Mar; 7(9):10133-52. PubMed ID: 26840086
[TBL] [Abstract][Full Text] [Related]
18. Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade.
Umelo IA; De Wever O; Kronenberger P; Van Deun J; Noor A; Singh K; Teugels E; Chen G; Bracke M; De Grève J
Oncotarget; 2015 Aug; 6(24):20132-44. PubMed ID: 25992771
[TBL] [Abstract][Full Text] [Related]
19. Combating HER2-overexpressing breast cancer through induction of calreticulin exposure by Tras-Permut CrossMab.
Zhang F; Zhang J; Liu M; Zhao L; LingHu R; Feng F; Gao X; Jiao S; Zhao L; Hu Y; Yang J
Oncoimmunology; 2015 Mar; 4(3):e994391. PubMed ID: 25949918
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
